Patents by Inventor Peter Muench
Peter Muench has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230120988Abstract: The present invention relates to a Corona antigen comprising a Corona nucleocapsid specific amino acid sequence, compositions, and reagent kits comprising the same and methods of producing it. Also encompassed are methods of detecting anti-Corona antibodies in samples using said Corona antigen, and methods of differential diagnosis of an immune response in a patient due to natural Corona infection or due to vaccination against Corona.Type: ApplicationFiled: April 22, 2021Publication date: April 20, 2023Inventors: Frederik Baumkoetter, Juliane Benz, Markus Eckl, Peter Muench, Alexander Riedel, Christian Scholz
-
Patent number: 11567079Abstract: The invention concerns soluble and antigenic HTLV p24 variants that can be fused to chaperones and their use in diagnostic applications such as immunoassays for detecting antibodies against HTLV-I or HTLV-II in an isolated biological sample. In particular, the invention relates to a soluble HTLV-I or HTLV-II p24 antigen comprising either the N- or the C-terminal domain of p24 and lacking the other domain. Moreover, the invention covers recombinant DNA molecules encoding these HTLV-I and -II fusion antigens as well as their recombinant production using expression vectors and host cells transformed with such expression vectors. In addition, the invention focuses on compositions of these HTLV p24 antigens with HTLV gp21 antigen and on an immunoassay method for detection of HTLV antibodies using the antigens of the invention. Also the use of HTLV p24 antigens in an in vitro diagnostic assay as well as a reagent kit for detection of anti-HTLV-antibodies comprising said HTLV antigens is encompassed.Type: GrantFiled: September 20, 2019Date of Patent: January 31, 2023Assignee: Roche Diagnostics Operations, Inc.Inventors: Elke Faatz, Christian Scholz, Peter Muench
-
Publication number: 20220220158Abstract: The disclosure relates to a polypeptide suitable for detecting antibodies against a flavivirus in an isolated biological sample having a flavivirus NS1 wing domain specific amino acid sequence, wherein no amino acid sequences from the NS1 ?-ladder domain of said flavivirus are present in the polypeptide. In an embodiment, the flavivirus is selected from Zika virus (ZIKV), West-Nile virus (WNV), Dengue virus types 1-4 (DENV1-4), tick-borne encephalitis virus (TBEV), yellow fever virus (YFV) and Japanese encephalitis virus (JEV). Also disclosed is a method for producing said flaviviral NS1 wing domain specific polypeptides, a method for detecting antibodies specific for a first flavivirus species, the use of said flaviviral NS1 wing domain specific polypeptides for detecting antibodies as well as a reagent kit for detecting said flavivirus antibodies that has a flavivirus NS1 wing domain polypeptide.Type: ApplicationFiled: March 28, 2022Publication date: July 14, 2022Inventors: Elke Faatz, Alexander Riedel, Christian Scholz, Peter Muench, Gloria Tabares, Mario Gloeck, Silke Luebcke, Juliane Benz
-
Patent number: 11319351Abstract: The disclosure relates to a polypeptide suitable for detecting antibodies against a flavivirus in an isolated biological sample having a flavivirus NS1 wing domain specific amino acid sequence, wherein no amino acid sequences from the NS1 ß-ladder domain of said flavivirus are present in the polypeptide. In an embodiment, the flavivirus is selected from Zika virus (ZIKV), West-Nile virus (WNV), Dengue virus types 1-4 (DENV1-4), tick-borne encephalitis virus (TBEV), yellow fever virus (YFV) and Japanese encephalitis virus (JEV). Also disclosed is a method for producing said flaviviral NS1 wing domain specific polypeptides, a method for detecting antibodies specific for a first flavivirus species, the use of said flaviviral NS1 wing domain specific polypeptides for detecting antibodies as well as a reagent kit for detecting said flavivirus antibodies that has a flavivirus NS1 wing domain polypeptide.Type: GrantFiled: October 25, 2019Date of Patent: May 3, 2022Assignee: Roche Diagnostics Operations, Inc.Inventors: Elke Faatz, Alexander Riedel, Christian Scholz, Peter Muench, Gloria Tabares, Mario Gloeck, Silke Luebcke, Juliane Benz
-
Patent number: 11312750Abstract: The disclosure concerns a polypeptide suitable for detecting antibodies against Zika virus in an isolated biological sample having a Zika virus NS1 wing domain specific amino acid sequence and variants thereof, wherein no further Zika virus specific amino acid sequences are present in the polypeptide. This polypeptide does not immunologically cross-react with antibodies raised against structurally related antigens from tick-borne encephalitis virus, Dengue virus 1-4, West Nile virus, yellow fever virus or Japanese encephalitis virus, but immunologically reacts with antibodies raised against full length Zika virus NS1 antigen. Also disclosed is a method of producing a soluble and immunoreactive Zika virus NS1 polypeptide as well as methods and kits for detecting antibodies specific for Zika virus in an isolated sample.Type: GrantFiled: October 25, 2019Date of Patent: April 26, 2022Assignee: Roche Diagnostics Operations, Inc.Inventors: Elke Faatz, Mario Gloeck, Peter Muench, Alexander Riedel, Christian Scholz, Gloria Tabares
-
Patent number: 11245156Abstract: A degassing unit for an electronics housing has a base body to be connected fluid-tightly to a rim of a pressure compensation opening of the electronics housing. The base body has a gas passage opening covered by a semipermeable membrane that enables passage of gaseous media but prevents passage of liquid and solids. A fluid-permeable protective screen with screen openings is arranged at an inner side of the base body across the gas passage opening. The base body has a thread engagement region for screw-connecting the degassing unit to the electronics housing. The protective screen has a screw through opening aligned with the thread engagement region of the base body. At the screw through opening, a thread engagement region of the protective screen is provided that fixes the protective screen by a threaded fastening element immediately relative to the electronics housing in a mounted state of the degassing unit.Type: GrantFiled: May 13, 2020Date of Patent: February 8, 2022Assignee: MANN+HUMMEL GmbHInventors: Robert Zbiral, Peter Muench
-
Publication number: 20210349090Abstract: The present description relates to a Corona antigen having a Corona nucleocapsid specific amino acid sequence, compositions, and reagent kits having the same and methods of producing it. Also encompassed are methods of detecting anti-Corona antibodies in samples using the Corona antigen, and methods of differential diagnosis of an immune response in a patient due to natural Corona infection or due to vaccination against Corona.Type: ApplicationFiled: May 6, 2020Publication date: November 11, 2021Applicant: Roche Diagnostics Operations, Inc.Inventors: Alexander Riedel, Christian Scholz, Peter Muench, Juliane Benz, Markus Eckl, Frederik Baumkoetter
-
Publication number: 20210333277Abstract: The present invention relates to a Corona antigen comprising a Corona nucleocapsid specific amino acid sequence, compositions, and reagent kits comprising the same and methods of producing it. Also encompassed are methods of detecting anti-Corona antibodies in samples using said Corona antigen, and methods of differential diagnosis of an immune response in a patient due to natural Corona infection or due to vaccination against Corona.Type: ApplicationFiled: April 23, 2020Publication date: October 28, 2021Applicant: Roche Diagnostics Operations, Inc.Inventors: Alexander Riedel, Christian Scholz, Peter Muench, Juliane Benz, Markus Eckl, Frederik Baumkoetter
-
Patent number: 11150247Abstract: The present disclosure relates to a method for detecting a core polypeptide of a hepatitis C virus (HCV) in a sample from a subject involving (a) contacting said sample with a base and with a surfactant having a cationic detergent, and (b) detecting a core polypeptide of the HCV in the sample. The present invention further relates to a method for pre-processing a sample from a subject for detection of HCV, involving contacting the sample with a base and with a surfactant having a cationic detergent; and to a pre-processing reagent for detecting HCV in a sample, having a base and a surfactant including a cationic detergent, wherein the surfactant also has a nonionic detergent. Moreover, the present disclosure further relates to kits, uses, and devices related to the methods disclosed.Type: GrantFiled: November 29, 2018Date of Patent: October 19, 2021Assignee: Roche Diagnostics Operations, Inc.Inventors: Ralf Bollhagen, Barbara Upmeier, Toralf Zarnt, Peter Muench, Manfred Ginter
-
Patent number: 10891266Abstract: A user virtual file system within a hierarchical storage system performs file handling. A user virtual file system scans, reads and analyses data or user behavior to create or modify at least one rule or metadata. The user virtual file system identifies logical or temporal relationships of files based on the at least one rule or the metadata. The user virtual file system groups identified related files in the at least one container. The user virtual file system moves the at least one container to different tiers of storage based on the at least one rule or the metadata.Type: GrantFiled: September 10, 2013Date of Patent: January 12, 2021Assignee: International Business Machines CorporationInventors: Hans-Guenter Kraemer, Peter Muench, Rolf Schaefer, Norbert J. Schuld
-
Publication number: 20200388807Abstract: A degassing unit for an electronics housing has a base body to be connected fluid-tightly to a rim of a pressure compensation opening of the electronics housing. The base body has a gas passage opening covered by a semipermeable membrane that enables passage of gaseous media but prevents passage of liquid and solids. A fluid-permeable protective screen with screen openings is arranged at an inner side of the base body across the gas passage opening. The base body has a thread engagement region for screw-connecting the degassing unit to the electronics housing. The protective screen has a screw through opening aligned with the thread engagement region of the base body. At the screw through opening, a thread engagement region of the protective screen is provided that fixes the protective screen by a threaded fastening element immediately relative to the electronics housing in a mounted state of the degassing unit.Type: ApplicationFiled: May 13, 2020Publication date: December 10, 2020Inventors: Robert Zbiral, Peter Muench
-
Publication number: 20200048312Abstract: The disclosure concerns a polypeptide suitable for detecting antibodies against Zika virus in an isolated biological sample having a Zika virus NS1 wing domain specific amino acid sequence and variants thereof, wherein no further Zika virus specific amino acid sequences are present in the polypeptide. This polypeptide does not immunologically cross-react with antibodies raised against structurally related antigens from tick-borne encephalitis virus, Dengue virus 1-4, West Nile virus, yellow fever virus or Japanese encephalitis virus, but immunologically reacts with antibodies raised against full length Zika virus NS1 antigen. Also disclosed is a method of producing a soluble and immunoreactive Zika virus NS1 polypeptide as well as methods and kits for detecting antibodies specific for Zika virus in an isolated sample.Type: ApplicationFiled: October 25, 2019Publication date: February 13, 2020Applicant: Roche Diagnostics Operations, Inc.Inventors: Elke Faatz, Mario Gloeck, Peter Muench, Alexander Riedel, Christian Scholz, Gloria Tabares
-
Publication number: 20200048313Abstract: The disclosure relates to a polypeptide suitable for detecting antibodies against a flavivirus in an isolated biological sample having a flavivirus NS1 wing domain specific amino acid sequence, wherein no amino acid sequences from the NS1 ß-ladder domain of said flavivirus are present in the polypeptide. In an embodiment, the flavivirus is selected from Zika virus (ZIKV), West-Nile virus (WNV), Dengue virus types 1-4 (DENV1-4), tick-borne encephalitis virus (TBEV), yellow fever virus (YFV) and Japanese encephalitis virus (JEV). Also disclosed is a method for producing said flaviviral NS1 wing domain specific polypeptides, a method for detecting antibodies specific for a first flavivirus species, the use of said flaviviral NS1 wing domain specific polypeptides for detecting antibodies as well as a reagent kit for detecting said flavivirus antibodies that has a flavivirus NS1 wing domain polypeptide.Type: ApplicationFiled: October 25, 2019Publication date: February 13, 2020Applicant: Roche Diagnostics Operations, Inc.Inventors: Elke Faatz, Alexander Riedel, Christian Scholz, Peter Muench, Gloria Tabares, Mario Gloeck, Silke Luebcke, Juliane Benz
-
Publication number: 20200033342Abstract: The invention concerns soluble and antigenic HTLV p24 variants that can be fused to chaperones and their use in diagnostic applications such as immunoassays for detecting antibodies against HTLV-I or HTLV-II in an isolated biological sample. In particular, the invention relates to a soluble HTLV-I or HTLV-II p24 antigen comprising either the N- or the C-terminal domain of p24 and lacking the other domain. Moreover, the invention covers recombinant DNA molecules encoding these HTLV-I and -II fusion antigens as well as their recombinant production using expression vectors and host cells transformed with such expression vectors. In addition, the invention focuses on compositions of these HTLV p24 antigens with HTLV gp21 antigen and on an immunoassay method for detection of HTLV antibodies using the antigens of the invention. Also the use of HTLV p24 antigens in an in vitro diagnostic assay as well as a reagent kit for detection of anti-HTLV-antibodies comprising said HTLV antigens is encompassed.Type: ApplicationFiled: September 20, 2019Publication date: January 30, 2020Inventors: Elke Faatz, Christian Scholz, Peter Muench
-
Patent number: 10466242Abstract: The invention concerns soluble and antigenic HTLV p24 variants that can be fused to chaperones and their use in diagnostic applications such as immunoassays for detecting antibodies against HTLV-I or HTLV-II in an isolated biological sample. In particular, the invention relates to a soluble HTLV-I or HTLV-II p24 antigen comprising either the N- or the C-terminal domain of p24 and lacking the other domain. Moreover, the invention covers recombinant DNA molecules encoding these HTLV-I and -II fusion antigens as well as their recombinant production using expression vectors and host cells transformed with such expression vectors. In addition, the invention focuses on compositions of these HTLV p24 antigens with HTLV gp21 antigen and on an immunoassay method for detection of HTLV antibodies using the antigens of the invention. Also the use of HTLV p24 antigens in an in vitro diagnostic assay as well as a reagent kit for detection of anti-HTLV-antibodies comprising said HTLV antigens is encompassed.Type: GrantFiled: August 25, 2016Date of Patent: November 5, 2019Assignee: Roche Diagnostics Operations, Inc.Inventors: Elke Faatz, Christian Scholz, Peter Muench
-
Publication number: 20190086412Abstract: The present disclosure relates to a method for detecting a core polypeptide of a hepatitis C virus (HCV) in a sample from a subject involving (a) contacting said sample with a base and with a surfactant having a cationic detergent, and (b) detecting a core polypeptide of the HCV in the sample. The present invention further relates to a method for pre-processing a sample from a subject for detection of HCV, involving contacting the sample with a base and with a surfactant having a cationic detergent; and to a pre-processing reagent for detecting HCV in a sample, having a base and a surfactant including a cationic detergent, wherein the surfactant also has a nonionic detergent. Moreover, the present disclosure further relates to kits, uses, and devices related to the methods disclosed.Type: ApplicationFiled: November 29, 2018Publication date: March 21, 2019Applicant: Roche Diagnostics Operations, Inc.Inventors: Ralf Bollhagen, Barbara Upmeier, Toralf Zarnt, Peter Muench, Manfred Ginter
-
Patent number: 10094828Abstract: The present invention concerns a composition of polypeptides suitable for detecting antibodies against Trypanosoma cruzi (T. cruzi) in an isolated biological sample consisting of three polypeptides 1F8, JL7 and Cruzipain. A method of producing a soluble and immunoreactive composition of polypeptides suitable for detecting antibodies against T. cruzi using said composition of polypeptides is also part of the invention. Moreover, the invention concerns a method for detecting antibodies specific for T. cruzi in an isolated sample wherein a composition of said T. cruzi polypeptides is used as well as a reagent kit comprising said composition of T. cruzi polypeptides.Type: GrantFiled: May 5, 2017Date of Patent: October 9, 2018Inventors: Peter Muench, Dieter Roessler, Christian Scholz, Barbara Upmeier, Toralf Zarnt
-
Publication number: 20180164314Abstract: Disclosed is a method for detecting a capsid polypeptide of a non-enveloped virus in a sample from a subject which includes (a) contacting the sample with a base, and (b) detecting a capsid polypeptide of the virus in the sample. Moreover, the present disclosure relates to a method for pre-processing a sample from a subject for detection of a virus, including contacting the sample with a base. Moreover, the present disclosure relates to kits, uses and devices related to these methods.Type: ApplicationFiled: February 9, 2018Publication date: June 14, 2018Applicant: Roche Diagnostics Operations, Inc.Inventors: Elke Faatz, Peter Muench, Mirko Ritter, Gloria Tabares
-
Publication number: 20170248597Abstract: The present invention concerns a composition of polypeptides suitable for detecting antibodies against Trypanosoma cruzi (T. cruzi) in an isolated biological sample consisting of three polypeptides 1F8, JL7 and Cruzipain. A method of producing a soluble and immunoreactive composition of polypeptides suitable for detecting antibodies against T. cruzi using said composition of polypeptides is also part of the invention. Moreover, the invention concerns a method for detecting antibodies specific for T. cruzi in an isolated sample wherein a composition of said T. cruzi polypeptides is used as well as a reagent kit comprising said composition of T. cruzi polypeptides.Type: ApplicationFiled: May 5, 2017Publication date: August 31, 2017Inventors: Peter Muench, Dieter Roessler, Christian Scholz, Barbara Upmeier, Toralf Zarnt
-
Publication number: 20170184591Abstract: The invention concerns soluble and antigenic HTLV p24 variants that can be fused to chaperones and their use in diagnostic applications such as immunoassays for detecting antibodies against HTLV-I or HTLV-II in an isolated biological sample. In particular, the invention relates to a soluble HTLV-I or HTLV-II p24 antigen comprising either the N- or the C-terminal domain of p24 and lacking the other domain. Moreover, the invention covers recombinant DNA molecules encoding these HTLV-I and -II fusion antigens as well as their recombinant production using expression vectors and host cells transformed with such expression vectors. In addition, the invention focuses on compositions of these HTLV p24 antigens with HTLV gp21 antigen and on an immunoassay method for detection of HTLV antibodies using the antigens of the invention. Also the use of HTLV p24 antigens in an in vitro diagnostic assay as well as a reagent kit for detection of anti-HTLV-antibodies comprising said HTLV antigens is encompassed.Type: ApplicationFiled: August 25, 2016Publication date: June 29, 2017Inventors: Elke Faatz, Christian Scholz, Peter Muench